ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Rugo on VEGF-A as an Avastin Response Predictor

Hope S. Rugo, MD
Published: Friday, Sep 16, 2011

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the AVADO trial that investigated VEGF levels as a predictor of response to antiangiogenesis agents, particularly bevacizumab (Avastin).

A retrospective analysis of the data present by David W. Miles, MD, suggested that if VEGF-A levels were divided into quartiles the highest quartet level predicted higher response rates to bevacizumab.

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, University of California, San Francisco, discusses the AVADO trial that investigated VEGF levels as a predictor of response to antiangiogenesis agents, particularly bevacizumab (Avastin).

A retrospective analysis of the data present by David W. Miles, MD, suggested that if VEGF-A levels were divided into quartiles the highest quartet level predicted higher response rates to bevacizumab.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x